Fulcrum Therapeutics Inc (FULC)

$7.25

+0.41

(+5.99%)

Market is closed - opens 7 PM, 23 Apr 2024

Insights on Fulcrum Therapeutics Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 759.0K → 871.0K (in $), with an average increase of 12.9% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 4 quarters, -21.61M → -24.75M (in $), with an average decrease of 4.7% per quarter

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 231.4% return, outperforming this stock by 271.7%

Performance

  • $6.85
    $7.26
    $7.25
    downward going graph

    5.52%

    Downside

    Day's Volatility :5.65%

    Upside

    0.14%

    downward going graph
  • $2.43
    $13.70
    $7.25
    downward going graph

    66.48%

    Downside

    52 Weeks Volatility :82.26%

    Upside

    47.08%

    downward going graph

Returns

PeriodFulcrum Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
7.89%
-0.7%
0.0%
6 Months
93.77%
9.2%
0.0%
1 Year
173.58%
3.5%
-1.3%
3 Years
-41.09%
12.3%
-22.1%

Highlights

Market Capitalization
423.6M
Book Value
$3.8
Earnings Per Share (EPS)
-1.59
Wall Street Target Price
13.25
Profit Margin
0.0%
Operating Margin TTM
-3213.78%
Return On Assets TTM
-28.56%
Return On Equity TTM
-44.84%
Revenue TTM
2.8M
Revenue Per Share TTM
0.05
Quarterly Revenue Growth YOY
27.200000000000003%
Gross Profit TTM
-70.4M
EBITDA
-108.5M
Diluted Eps TTM
-1.59
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.75
EPS Estimate Next Year
-1.71
EPS Estimate Current Quarter
-0.43
EPS Estimate Next Quarter
-0.44

Analyst Recommendation

Buy
    76%Buy
    15%Hold
    7%Sell
Based on 13 Wall street analysts offering stock ratings for Fulcrum Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 13 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
8
Hold
2
2
4
Sell
1
1
1

Analyst Forecast

What analysts predicted

Upside of 82.76%

Current $7.25
Target $13.25

Technicals Summary

Sell

Neutral

Buy

Fulcrum Therapeutics Inc is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Fulcrum Therapeutics Inc
Fulcrum Therapeutics Inc
-23.12%
93.77%
173.58%
-41.09%
-46.3%
Moderna, Inc.
Moderna, Inc.
-3.81%
28.95%
-26.59%
-39.67%
329.16%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-7.28%
12.73%
12.52%
82.86%
168.48%
Novo Nordisk A/s
Novo Nordisk A/s
-4.7%
26.35%
43.96%
230.98%
410.23%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-3.87%
7.24%
20.15%
82.55%
128.04%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Fulcrum Therapeutics Inc
Fulcrum Therapeutics Inc
NA
NA
NA
-1.75
-0.45
-0.29
NA
3.8
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.72
25.72
1.46
45.22
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.32
46.32
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.33
28.33
0.53
16.77
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Fulcrum Therapeutics Inc
Fulcrum Therapeutics Inc
Buy
$423.6M
-46.3%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$38.8B
329.16%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.1B
168.48%
25.72
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$550.4B
410.23%
46.32
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$101.7B
128.04%
28.33
36.68%

Institutional Holdings

  • RA Capital Management, LLC

    18.74%
  • FMR Inc

    9.18%
  • Suvretta Capital Management, LLC

    8.91%
  • RTW INVESTMENTS, LLC

    8.83%
  • COWEN AND COMPANY, LLC

    5.61%
  • Vanguard Group Inc

    4.07%

Corporate Announcements

  • Fulcrum Therapeutics Inc Earnings

    Fulcrum Therapeutics Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

what if we could regulate genes, not just discover them? what if we could treat disease at their genetic source? what if we could integrate multiple disciplines to develop breakthrough medicines? what if you could be a part of a passionate team committed to the patients we serve? we can. we will. we are. join us. we are here to develop new medicines to deliver a new future for patients and their families by transforming gene regulation in disease. a fulcrum is defined as the point on which a lever rests, balances and pivots. fulcrum therapeutics is intervening in gene regulatory mechanisms to unlock the information contained in the human genome. the fulcrum product engine is dedicated to bringing balance to the genetic on and off switches in disease. our approach the sequencing of the human genome has provided incredible insight into disease biology, yet the richness of biology comes from the dynamic on and off switches that control the genome – gene regulation. the fulcrum product eng

Organization
Fulcrum Therapeutics Inc
Employees
76
CEO
Mr. Alexander C. Sapir
Industry
Health Technology

FAQs